Inagen Overview

  • Founded
  • 2007
  • Status
  • Out of Business
  • Employees
  • 3
  • Latest Deal Type
  • Out of Business

Inagen General Information


Developer of new forms of therapies designed to develop therapeutics for the treatment of selected types of viral diseases. The company's technology utilizes a "self targeting capability", which takes place in the natural defense mechanism of the specific disease, to target and kill infected cells.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Diplomvej 378
  • 2800 Lyngby
  • Denmark
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inagen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 00000 Completed Out of Business
2. Later Stage VC 22-Dec-2008 00000 00000 Completed Startup
1. Early Stage VC 01-Dec-2007 Completed Startup
To view Inagen’s complete valuation and funding history, request access »

Inagen Executive Team (2)

Name Title Board Seat Contact Info
Mette Rosenkilde Ph.D Co-Founder
You’re viewing 1 of 2 executive team members. Get the full list »

Inagen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial